Fig. 6. Efficacy of ExtraCRAd in a pre-immunization set-up in melanoma and lung cancer models.
a Long-term overall survival of C57BL/6 mice injected with 7 × 106 CMT64.OVA subcutaneously in the flank. b Long-term overall survival of C57BL/6 mice injected with 1 × 105 B16.F10 cells subcutaneously in the flank. In both the models, animals were removed from the survival curve upon sacrifice. Mice dead for causes not imputable to the tumor growth or mice still alive at the completion of the study were censored in the survival curves. The data were analyzed with log-rank (Mantel–Cox) curve comparison. The levels of significance were set at *p < 0.05, **p < 0.01, and *** p < 0.001. Mean tumor growth curve (mm3) in c the CMT64.OVA model and d the B16.F10 model. The data are presented as mean ± SEM (n = 6). The data were analyzed with two-way ANOVA followed by Tukey’s (c) and Fisher’s (d) post test. The levels of significance were set at probabilities of *p < 0.05 and ****p < 0.0001. The error bars represent SEM.